Shared decision-making in HCM

[1]  B. Maron,et al.  Demographics and Epidemiology of Sudden Deaths in Young Competitive Athletes: From the United States National Registry. , 2016, The American journal of medicine.

[2]  B. Maron.  Saving Lives One at a Time. , 2016, JAMA cardiology.

[3]  B. Maron,et al.  Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. , 2016, Heart rhythm.

[4]  B. Maron,et al.  How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice. , 2016, JAMA cardiology.

[5]  M. Link,et al.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat , 2015, Journal of the American College of Cardiology.

[6]  Martin Borggrefe,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[7]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[8]  E. Hess,et al.  Implementation of Shared Decision Making in Cardiovascular Care: Past, Present, and Future , 2014, Circulation. Cardiovascular quality and outcomes.

[9]  P. Elliott.  Myotonic dystrophy: time for evidence-based therapy. , 2014, European heart journal.

[10]  M. Barry,et al.  Shared decision making--pinnacle of patient-centered care. , 2012, The New England journal of medicine.

[11]  B. Maron,et al.  Competitive athletes with cardiovascular disease--the case of Nicholas Knapp. , 1998, The New England journal of medicine.

[12]  M. Link,et al.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat , 2015, Journal of the American College of Cardiology.

[13]  J. Stockman.  Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy , 2009 .

[14]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.